low volume 1.5L PEG-ELS

PreclinicalSmall molecule

NNational Taiwan University Hospital

low volume 1.5L PEG-ELS is one of 5 small molecule programs targeting Acceptability. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AcceptabilityCompleted

AcceptabilityPreclinical

Completed

Competition

Competitive Landscape

6 competitors in Acceptability

#DrugCompanyPhaseTrials

Jadelle

IItalian Network for Tumor Biotherapy Foundation

Phase 3

3 2

Mifeprex

DDanco

Phase 3

2 3

Verazinc

FFakultas Kedokteran Universitas Indonesia

Preclinical

1 4

Nuvaring

UUniversity of Washington

Preclinical

1 5

low volume 1.5L PEG-ELS

NNational Taiwan University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acceptability1 trial

Efficacy and Acceptability of Low-Residue Diet Package (Enimaclin®) as Diet Control Before Colonoscopy

Completed·NNational Taiwan University Hospital·N/A·NCT01665157·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for low volume 1.5L PEG-ELS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — low volume 1.5L PEG-ELS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for low volume 1.5L PEG-ELS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Taiwan University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Taiwan University Hospital

low volume 1.5L PEG-ELS

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acceptability1 trial

References

Drug Info

Quick Facts

Related News